1
|
Rodríguez M, Tomás‐Roca L, Alonso‐Alonso R, Manso‐Alonso R, Cereceda L, Borregón J, Villaescusa T, Raúl Córdoba, Sánchez‐Beato M, Fernández‐Miranda I, Betancor I, Bárcena C, García JF, Mollejo M, García‐Cosio M, Martin‐Acosta P, Climent F, Caballero D, Mondéjar R, Kessler L, Scholz C, Gualberto A, Rodríguez‐Pinilla SM, Piris MÁN. PERIPHERAL T‐CELL LYMPHOMA: MOLECULAR PROFILING DISTINGUISHES SUBCLASSES, RECOGNIZES THE TUMOR ARCHITECTURE AND IDENTIFIES PROGNOSTIC MARKERS. Hematol Oncol 2021. [DOI: 10.1002/hon.140_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M Rodríguez
- Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz University Hospital CIBERONC. Madrid, Spain, Pathology Department Madrid Spain
| | - L Tomás‐Roca
- Pathology Department Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz University Hospital Pathology Department Madrid Spain
| | - R Alonso‐Alonso
- Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz University Hospital CIBERONC. Madrid, Spain, Pathology Department Madrid Spain
| | - R Manso‐Alonso
- Pathology Department Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz University Hospital Pathology Department Madrid Spain
| | - L Cereceda
- Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz University Hospital CIBERONC. Madrid, Spain, Pathology Department Madrid Spain
| | - J Borregón
- Pathology Department Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz University Hospital Pathology Department Madrid Spain
| | - T Villaescusa
- Fundación Jiménez Díaz University Hospital, Health Research Institute IIS‐FJD, Madrid, Spain Department of Hematology Madrid Spain
| | - Raúl Córdoba
- Fundación Jiménez Díaz University Hospital Health Research Institute IIS‐FJD, CIBERONC, Madrid, Spain Department of Hematology Madrid Spain
| | - M Sánchez‐Beato
- Instituto de Investigación Sanitaria Puerta de Hierro‐Segovia de Arana, CIBERONC, Madrid, Spain Lymphoma Research Group, Medical Oncology Department Madrid Spain
| | - I Fernández‐Miranda
- nstituto de Investigación Sanitaria Puerta de Hierro‐Segovia de Arana, Madrid, Spain Lymphoma Research Group, Medical Oncology Department Madrid Spain
| | - I Betancor
- Pathology Department Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz University Hospital Pathology Department Madrid Spain
| | - C Bárcena
- Hospital Universitario 12 de Octubre, Madrid, Spain Pathology Department Madrid Spain
| | - J. F García
- Hospital MD Anderson Cancer Center, CIBERONC, Madrid, Spain Pathology Department Madrid Spain
| | - M Mollejo
- Hospital Virgen de la Salud, CIBERONC, Toledo, Spain Pathology Department Toledo
| | - MóN. García‐Cosio
- Hospital Universitario Ramón y Cajal, CIBERONC, Madrid, Spain Pathology Department Madrid Spain
| | - P Martin‐Acosta
- Hospital Universitario Puerta de Hierro‐Segovia de Arana, CIBERONC, Madrid, Spain Pathology Department Madrid Spain
| | - F Climent
- Hospital Universitari de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain Pathology Department Barcelona
| | - D Caballero
- Hospitalario Universitario de Salamanca (HUS/IBSAL), Salamanca, Spain Haematology Department Salamanca Spain
| | - R Mondéjar
- Hospital Universitario Virgen del Rocío, CIBERONC, Sevilla, Spain, Laboratory Sevilla Spain
| | - L Kessler
- Kura Oncology Inc., Kura Oncology Inc., San Diego California USA
| | - C Scholz
- Kura Oncology Inc., Kura Oncology Inc., San Diego California USA
| | - A Gualberto
- Kura Oncology Inc., Kura Oncology Inc., San Diego California USA
| | - S. M Rodríguez‐Pinilla
- Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz University Hospital CIBERONC. Madrid, Spain, Pathology Department Madrid Spain
| | - MÁN. Piris
- Instituto de Investigación Sanitaria‐Fundación Jiménez Díaz University Hospital CIBERONC. Madrid, Spain, Pathology Department Madrid Spain
| |
Collapse
|
2
|
Rodriguez M, Alonso R, Rodriguez-Pinilla S, Cereceda L, Villaescusa T, Cordoba R, Sánchez-Beato M, Fernandez-Miranda I, Bárcena C, García J, Mollejo M, Garcia-Cosio M, Martin-Acosta P, Climent F, Caballero D, Kessler L, Scholz C, Gualberto A, Mondéjar R, Piris M. A PTCL GENE SIGNATURE CAPTURING STROMAL AND NEOPLASTIC DATA STRATIFIES PTCL/NOS AND AITL INTO DIFFERENT GROUPS WITH VARIABLE SURVIVAL PROBABILITY. Hematol Oncol 2019. [DOI: 10.1002/hon.22_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Rodriguez
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - R. Alonso
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - S. Rodriguez-Pinilla
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - L. Cereceda
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - T. Villaescusa
- Haematology; Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - R. Cordoba
- Haematology; Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - M. Sánchez-Beato
- Medical Oncology; Instituto Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - I. Fernandez-Miranda
- Medical Oncology; Instituto Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - C. Bárcena
- Pathology; Hospital Universitario 12 de Octubre; Madrid Spain
| | - J. García
- Pathology; Hospital MD Anderson Cancer Center; Madrid Spain
| | - M. Mollejo
- Pathology; Hospital Virgen de la Salud; Toledo Spain
| | - M. Garcia-Cosio
- Pathology; Instituto de Investigación Hospital Ramón y Cajal; Madrid Spain
| | - P. Martin-Acosta
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - F. Climent
- Pathology; Hospital Universitario de Bellvitge; Barcelona Spain
| | - D. Caballero
- Haematology; Hospital Clínico Universitario de Salamanca; Salamanca Spain
| | - L. Kessler
- Kura Oncology; San Diego; CA United States
| | - C. Scholz
- Kura Oncology; Cambridge; MA United States
| | | | - R. Mondéjar
- Haematology; Hospital Universitario Virgen del Rocío; Sevilla Spain
| | - M. Piris
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| |
Collapse
|
3
|
Rodriguez M, Fernandez-Miranda I, Mondejar R, Capote J, Rodriguez-Pinilla S, Cereceda L, Alonso R, Cordoba R, Provencio M, Martin-Acosta P, Sanchez A, Pedrosa L, Gómez S, Piris-Villaespesa M, Garcia-Cosio M, Quero C, Llanos M, Barcena C, Fraga M, Camacho F, Castro Y, Garcia J, Mollejo M, Climent F, Mayordomo E, Bacalari E, Olmedilla G, Sánchez-Beato M, Piris M. DIFFUSE LARGE B-CELL LYMPHOMA SURVIVAL PROGNOSTICATION, A COMPARATIVE ANALYSIS OF CELL OF ORIGIN VS. MYC/BCL2 EXPRESSION. Hematol Oncol 2019. [DOI: 10.1002/hon.15_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Rodriguez
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - I. Fernandez-Miranda
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - R. Mondejar
- Haematology; Hospital Universitario Virgen del Rocío, Sevilla; Spain
| | - J. Capote
- Medical Oncology; Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - S. Rodriguez-Pinilla
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - L. Cereceda
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - R. Alonso
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - R. Cordoba
- Haematology; Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| | - M. Provencio
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - P. Martin-Acosta
- Pathology; Instituto Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - A. Sanchez
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - L. Pedrosa
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - S. Gómez
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | | | - M. Garcia-Cosio
- Haematology; Instituto de Investigación Hospital Ramón y Cajal; Madrid Spain
| | - C. Quero
- Medical Oncology; Hospital Universitario Virgen de la Victoria; Málaga Spain
| | - M. Llanos
- Medical Oncology; Hospital Universitario de Canarias; Santa Cruz de Tenerife Spain
| | - C. Barcena
- Pathology; Instituto de Investigación Hospital 12 de Octubre; Madrid Spain
| | - M. Fraga
- Pathology; Hospital Clínico Universitario de Santiago-CHUS, Santiago de Compostela; A Coruña Spain
| | - F. Camacho
- Pathology; Hospital Universitario de Getafe; Madrid Spain
| | - Y. Castro
- Pathology; Hospital Universitario Príncipe de Asturias; Madrid Spain
| | - J. Garcia
- Pathology; Hospital MD Anderson Cancer Center; Madrid Spain
| | - M. Mollejo
- Pathology; Hospital Virgen de la Salud; Toledo Spain
| | - F. Climent
- Pathology; Hospital Universitario de Bellvitge; Barcelona Spain
| | - E. Mayordomo
- Pathology; Hospital Universitario y Politécnico de La Fe; Valencia Spain
| | - E. Bacalari
- Pathology; Hospital Universitario La Paz; Madrid Spain
| | - G. Olmedilla
- Pathology; Hospital Universitario La Paz; Madrid Spain
| | - M. Sánchez-Beato
- Medical Oncology; Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana; Madrid Spain
| | - M. Piris
- Pathology; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Fundación Jiménez Díaz; Madrid Spain
| |
Collapse
|
4
|
Gualberto A, Scholz C, Mishra V, Kessler L, Rodriguez M, Piris M, Witzig T. KIR3DL2 MUTATION MAY DEFINE A HIGH RATE OF RESPONSE OF AITL TO TIPIFARNIB. Hematol Oncol 2019. [DOI: 10.1002/hon.20_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- A. Gualberto
- Development; Kura Oncology, Inc.; Cambridge United States
| | - C. Scholz
- Development; Kura Oncology, Inc.; Cambridge United States
| | - V. Mishra
- Development; Kura Oncology, Inc.; San Diego United States
| | - L. Kessler
- Development; Kura Oncology, Inc.; San Diego United States
| | | | - M. Piris
- Pathology; Fundación Jiménez Díaz; Madrid Spain
| | - T. Witzig
- Hematology; Hematopathology, Mayo Clinic; Rochester United States
| |
Collapse
|
5
|
Mitxelena I, Piris M, Rodríguez-Mayorga M. On the performance of natural orbital functional approximations in the Hubbard model. J Phys Condens Matter 2017; 29:425602. [PMID: 28722686 DOI: 10.1088/1361-648x/aa80ca] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Strongly correlated materials are now under intense development, and natural orbital functional (NOF) methods seem to be able to capture the physics of these systems. We present a benchmark based on the Hubbard model for a class of commonly used NOF approximations (also known as reduced density matrix functional approximations). Our findings highlight the importance of imposing ensemble N-representability conditions in order to obtain consistent results in systems with either weak or strong electronic correlation, such as the Hubbard system with a varying two-particle interaction parameter. Based on the accuracy of the results obtained using PNOF7, which retrieves a large amount of the total strong nondynamic correlation, the Hubbard model points out that N-representability gives solid foundations for NOF development.
Collapse
Affiliation(s)
- I Mitxelena
- Donostia International Physics Center (DIPC), 20018 Donostia, Euskadi, Spain. Kimika Fakultatea, Euskal Herriko Unibertsitatea (UPV/EHU), 20018 Donostia, Euskadi, Spain
| | | | | |
Collapse
|
6
|
Witzig T, Sokol L, Jacobsen E, Advani R, Mondejar R, Piris M, Burrows F, Melvin C, Mishra V, Scholz C, Gualberto A. PRELIMINARY RESULTS FROM AN OPEN-LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_115] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- T. Witzig
- Laboratory Medicine and Pathology; Mayo Clinic; Rochester USA
| | - L. Sokol
- Medical Oncology; H. Lee Moffitt Cancer Center & Research Institute; Tampa USA
| | - E. Jacobsen
- Medical Oncology; Dana Farber Cancer Institute; Boston USA
| | - R. Advani
- Medicine - Med/Oncology; Stanford Cancer Institute; Palo Alto USA
| | - R. Mondejar
- Laboratorio de Genómica del Cáncer, IDIVAL-Instituto de Investigación Marqués de Valdecilla; Santander Spain
| | - M. Piris
- Pathology Service, Fundación Jiménez Díaz; Madrid Spain
| | - F. Burrows
- Research & Development; Kura Oncology; La Jolla USA
| | - C. Melvin
- Research & Development; Kura Oncology; La Jolla USA
| | - V. Mishra
- Research & Development; Kura Oncology; La Jolla USA
| | - C. Scholz
- Research & Development; Kura Oncology; La Jolla USA
| | - A. Gualberto
- Research & Development; Kura Oncology; La Jolla USA
| |
Collapse
|
7
|
Piris M, March NH. Low-Lying Isomers of Free-Space Halogen Clusters with Tetrahedral and Octahedral Symmetry in Relation to Stable Molecules Such as SF6. J Phys Chem A 2015; 119:10190-4. [DOI: 10.1021/acs.jpca.5b02788] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- M. Piris
- Donostia International Physics Center (DIPC), Paseo Manuel de Lardizabal, 4, 20018 Donostia, Euskadi, Spain
- Kimika Fakultatea, Euskal Herriko Unibertsitatea (UPV/EHU), Manuel Lardiazabal
Pasealekua, 3, 20018 Donostia, Euskadi, Spain
- IKERBASQUE, Basque Foundation for Science, Maria Diaz de Haro 3, 48011 Bilbao, Euskadi, Spain
| | - N. H. March
- Donostia International Physics Center (DIPC), Paseo Manuel de Lardizabal, 4, 20018 Donostia, Euskadi, Spain
- Department
of Physics, University of Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium
- Department of Physics, Oxford University, Parks Road, OX1 3PU Oxford, England
| |
Collapse
|
8
|
|
9
|
|
10
|
|
11
|
|
12
|
|
13
|
Ruipérez F, Piris M, Ugalde JM, Matxain JM. The natural orbital functional theory of the bonding in Cr2, Mo2and W2. Phys Chem Chem Phys 2013; 15:2055-62. [DOI: 10.1039/c2cp43559d] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
14
|
Piris M, Lopez X, Ruipérez F, Matxain JM, Ugalde JM. A natural orbital functional for multiconfigurational states. J Chem Phys 2011; 134:164102. [DOI: 10.1063/1.3582792] [Citation(s) in RCA: 106] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Matxain JM, Piris M, Ruipérez F, Lopez X, Ugalde JM. Homolytic molecular dissociation in natural orbital functional theory. Phys Chem Chem Phys 2011; 13:20129-35. [DOI: 10.1039/c1cp21696a] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
16
|
Piris M, Matxain JM, Lopez X, Ugalde JM. Communication: The role of the positivity N-representability conditions in natural orbital functional theory. J Chem Phys 2010; 133:111101. [DOI: 10.1063/1.3481578] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Piris M, Matxain JM, Lopez X, Ugalde JM. Communications: Accurate description of atoms and molecules by natural orbital functional theory. J Chem Phys 2010; 132:031103. [DOI: 10.1063/1.3298694] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
18
|
Lopez X, Piris M, Matxain JM, Ugalde JM. Performance of PNOF3 for reactivity studies: X[BO] and X[CN] isomerization reactions (X = H, Li) as a case study. Phys Chem Chem Phys 2010; 12:12931-4. [DOI: 10.1039/c003379k] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
19
|
|
20
|
|
21
|
Piris M, Matxain JM, Ugalde JM. Piris natural orbital functional study of the dissociation of the radical helium dimer. J Chem Phys 2008; 129:014108. [DOI: 10.1063/1.2950094] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
|
23
|
Abstract
The authors have investigated the description of the dispersion interaction within the Piris natural orbital functional (PNOF) theory. The PNOF arises from an explicit antisymmetric approach for the two-particle cumulant in terms of two symmetric matrices, Delta and Lambda. The functional forms of these matrices are obtained from the generalization of the two-particle system expressions, except for the off-diagonal elements of Delta. The mean value theorem and the partial sum rule obtained for the off-diagonal elements of Delta provide a prescription for deriving practical functionals. In particular, the previous employed approximation {Jpp/2} for the mean values {Jp*} affords several molecular properties but it is incapable to account for dispersion effects. In this work, the authors analyze a new approach for Jp* obtained by factorization of the matrix Delta within the bounds on its off-diagonal elements imposed by the positivity conditions of the two-particle reduced density matrix. Additional terms for the matrix elements of Lambda proportional to the square root of the holes are again introduced to describe properly the occupation numbers of the lowest occupied levels. The authors have found that the cross products between weakly occupied orbitals must be removed from the functional form of Lambda to obtain a correct long-range asymptotic behavior. The PNOF is used to predict the binding energy as well as the equilibrium distance of the helium dimer. The results are compared with the full configuration-interaction calculations and the corresponding experimental data.
Collapse
Affiliation(s)
- M Piris
- Kimika Fakultatea, Euskal Herriko Unibertsitatea, Donostia International Physics Center (DIPC), P.K. 1072, 20080 Donostia, Euskadi, Spain
| | | | | |
Collapse
|
24
|
Abstract
The Piris natural orbital functional (PNOF) based on a new approach for the two-electron cumulant has been used to predict adiabatic ionization potentials, equilibrium bond distances, and harmonic vibrational frequencies of 18 diatomic molecules. Vertical ionization potentials have been calculated for the same set of diatomic molecules and another set of 20 polyatomic molecules using energy-difference methods as well as the extended Koopman theorem. The PNOF properties compare favorably with the coupled-cluster-doubles results. The calculated PNOF values are in good agreement with the corresponding experimental data, considering the basis sets used (6-31G**).
Collapse
Affiliation(s)
- P Leiva
- Institute of Physical and Theoretical Chemistry, Friedrich-Alexander-University Erlangen-Nuremberg, Egerlandstrasse 3, 91058 Erlangen, Germany
| | | |
Collapse
|
25
|
Castillo AS, Artiga M, Perez-Rosado A, Nogales F, Piris M. 233 Activation of NFkB pathway in diffuse large B-cell lymphoma. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80241-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
26
|
Sosa-Albertus M, Piris M. Conformational analysis of 3,3-disubstituted benzoylthioureas using X-ray diffraction and ab initio calculations. J Mol Struct 2001. [DOI: 10.1016/s0022-2860(01)00626-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
27
|
Delsol G, Diebold J, Isaacson PG, Müller-Hermelink K, Piris M, Stutte HJ, Van Krieken JH. Pathology of the spleen: report on the workshop of the VIIIth meeting of the European Association for Haematopathology, Paris 1996. Histopathology 1998; 32:172-9. [PMID: 9543675 DOI: 10.1046/j.1365-2559.1998.00311.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- G Delsol
- Service central d'Anatomie et de Cytologie Pathologiques, Hopital Purpan, Toulouse, France
| | | | | | | | | | | | | |
Collapse
|
28
|
Piris M, Montero LA, Cruz N. The Bardeen–Cooper–Schrieffer approach to electron correlation in the density matrix formalism. J Chem Phys 1997. [DOI: 10.1063/1.474363] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Abstract
The CD30 antigen is a characteristic phenotypic feature of Sternberg-Reed and Hodgkin cells and is also found in a subset of large cell non-Hodgkin's lymphomas. The finding of CD30 positive cells in some centroblastic/centrocytic (cb/cc) follicular lymphomas prompted us to characterize the presence and distribution of CD30 positive cells in this type of lymphoma, using the monoclonal antibody BerH2. CD30 positive cells were present in 17/19 of the cases studied, located mainly at the edge of the neoplastic follicles, but also in some cases in perinodular or T-cell areas. This distribution resembles that found in reactive tonsils and lymph nodes. The majority of these CD30 positive cells in cb/cc lymphoma seem to be B-cells, as suggested by their reactivity with B-cell markers demonstrated by double immunostaining. The nature of these CD30 positive cells is unclear, but they should be taken into consideration in the differential diagnosis of cb/cc lymphoma with lymphocyte predominance Hodgkin's disease.
Collapse
Affiliation(s)
- M Piris
- Nuffield Department of Pathology, John Radcliffe Hospital, Oxford, UK
| | | | | |
Collapse
|
30
|
Abstract
The CD30 antigen has been reported as the immunophenotypic hallmark of a recently described category of non-Hodgkin's lymphoma, termed anaplastic large cell lymphoma. From a series of approximately 500 lymphomas, 17 cases showing typical anaplastic features have been identified. They were strongly labelled by monoclonal antibodies recognizing CD30 (Ki-1 or BerH2). However, 36 other lymphomas, mainly high-grade, of non-anaplastic cytology also expressed CD30, either diffusely or focally, with a staining pattern identical to that seen in anaplastic large cell lymphomas. This clearly suggests that such lymphomas cannot be identified solely on the basis of being high-grade non-Hodgkin's lymphomas showing CD30 positivity. From the present results, the distinction between the anaplastic and non-anaplastic types would be better made with antibodies to epithelial membrane antigen than to CD30. Clinical data, available for 48 of the patients (16 with anaplastic large cell lymphomas and 32 with non-anaplastic) revealed no significant differences with regard to age at presentation, sex or clinical signs. A short-term follow-up study of 25 patients revealed that for the first 2 years after diagnosis there were no significant differences in patient survival between anaplastic large cell lymphoma, other CD30+ high-grade lymphomas and all high-grade non-Hodgkin's lymphomas considered together. These findings, which must be confirmed by larger studies, suggest that in a general lymphoma clinic there is probably little justification for differentiating anaplastic large cell lymphomas or CD30+ lymphomas from other high-grade non-Hodgkin's lymphomas.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Anaplasia
- Antigens, Differentiation/metabolism
- Antigens, Neoplasm/metabolism
- Child
- Female
- Humans
- Immunohistochemistry
- Ki-1 Antigen
- Lymphoma, Large B-Cell, Diffuse/immunology
- Lymphoma, Large B-Cell, Diffuse/pathology
- Lymphoma, Non-Hodgkin/classification
- Lymphoma, Non-Hodgkin/immunology
- Lymphoma, Non-Hodgkin/pathology
- Male
- Middle Aged
Collapse
Affiliation(s)
- M Piris
- Nuffield Department of Pathology, John Radcliffe Hospital, Oxford, UK
| | | | | | | |
Collapse
|
31
|
Rivas C, Obeso G, Piris M, Castrillo JM, Bellas C, Acevedo A, Martín C, Campo E, Gamallo C, Font M. [Ki-1 non-Hodgkin's lymphoma. A multihospital study of 21 cases]. Rev Clin Esp 1989; 184:238-44. [PMID: 2549584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The Ki-1 monoclonal antibody recognizes a specific membrane antigen of activated lymphoid cells and stains large-cell non Hodgkin's lymphomas and Hodgkin's disease. Thus, it is widely used in the diagnosis of anaplastic lymphomas. Morphologically, the Ki-1 monoclonal non Hodgkin's lymphoma are diffuse of multifocal either classical or cell anaplastic type. The clinical behaviour is similar to the rest of the high grade lymphomas, disseminated at diagnosis but may reach remission after aggressive chemotherapy. The immunophenotype showed T, B or null nature of the latter. The clinical and pathological results of our study carried out in a group of 21 cases ki-1 positive lymphomas is herewith reported.
Collapse
|